Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3186914 | 0.88 | PDK2 (0.56) | PDK2USP30KMT2APTPN2PTPN1 | |
| SCHEMBL3179424 | 0.85 | NPC1 (0.51) | PDK2USP30KMT2APTPN2PTPN1 | |
| SCHEMBL3189609 | 0.84 | USP30 (0.51) | USP30KMT2AMEN1PTPN2PTPN1 | |
| SCHEMBL27730489 | 0.84 | PDK2 (0.43) | PDK2USP30KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3734439 | 0.83 | PTPRB (0.55) | USP30KMT2AMEN1GPR119STS | |
| SCHEMBL27178814 | 0.81 | PDK2 (0.54) | PDK2USP30KMT2AMEN1PTPN2 | |
| SCHEMBL4875392 | 0.81 | USP30 (0.47) | USP30KMT2AMEN1NPC1 | |
| SCHEMBL3171133 | 0.78 | PTPN2 (0.58) | KMT2APTPN2PTPN1PTPN6GPR119 | |
| SCHEMBL18183705 | 0.78 | PTPN2 (0.48) | KMT2AMEN1PTPN2PTPN1PTPN6 | |
| SCHEMBL27178869 | 0.78 | PDK2 (0.51) | PDK2USP30KMT2APTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522669-A1 | 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | Janssen Pharmaceutica NV (BE) | 2012-11-14 | — | — | EP | disclosed |
| US-7655670-B2 | 1-((tetrahydropyran-2-yl)oxy-ethyl)-5-tert-butoxycarbonyl-spiro[indoline-3,4'-piperidin]-2-one; ORL-1 (orphan opioid receptor) G-protein coupled receptor; brain, psychological disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-02 | — | — | US | disclosed |
| US-7655670-B2 | 1-((tetrahydropyran-2-yl)oxy-ethyl)-5-tert-butoxycarbonyl-spiro[indoline-3,4'-piperidin]-2-one; ORL-1 (orphan opioid receptor) G-protein coupled receptor; brain, psychological disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-02 | — | — | US | disclosed |
| US-7655670-B2 | 1-((tetrahydropyran-2-yl)oxy-ethyl)-5-tert-butoxycarbonyl-spiro[indoline-3,4'-piperidin]-2-one; ORL-1 (orphan opioid receptor) G-protein coupled receptor; brain, psychological disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-02 | — | — | US | disclosed |
| EP-1890696-A2 | NOVEL 3-SPIROCYCLIC INDOLYL DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-17 | — | — | US | disclosed |
| WO-2006130416-A2 | NOVEL 3-SPIROCYCLIC INDOLYL DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | OXER1, OGFRL1, NR1H2 | PDK2 1711/4885USP30 3051/4885KMT2A 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.